A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION
A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION is a paper indexed in PICO Portal from OpenAlex.
How many citations does A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION have?
A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION has 166 citations in the OpenAlex counts PICO Portal stores.
When was A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION published?
A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION has 1999 year in the PICO Portal index.
What is the open-access status of A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION?
A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION has closed oa status in the PICO Portal index.
What is the DOI of A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION?
The DOI for A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION is on the source record.
What is the PMID of A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION?
The PMID for A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION is on the source record.
What is the OpenAlex record for A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION?
The OpenAlex for A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION is on the source record.